Natriuretic polypeptides

Patent metadata

Field	Value
Publication number	US-9587004-B2
Application number	US-201615232429-A
Country	US
Kind code	B2
Filing date	Aug 9, 2016
Priority date	Aug 30, 2011
Publication date	Mar 7, 2017
Grant date	Mar 7, 2017

Abstract

This document provides methods and materials related to natriuretic polypeptides and the use of natriuretic polypeptides to treat cardiovascular and/or renal conditions. For example, chimeric polypeptides having at least one amino acid segment (e.g., N-terminus tail, ring structure, C-terminus tail, or a combination thereof) of a natriuretic peptide (e.g., ANP, BNP, CNP, URO, or DNP) and an amino acid segment of an angiotensin polypeptide (e.g., Ang-(1-7)) are provided.

First claim

What is claimed is:

1. A polypeptide from 20 to 28 amino acid residues in length, wherein said polypeptide comprises, in an order from amino terminus to carboxy terminus:
(a) the sequence set forth in SEQ ID NO: 1 or the sequence set forth in SEQ ID NO: 1 with no more than two additions, deletions, or substitutions, and
(b) the sequence set forth in SEQ ID NO:7 or the sequence set forth in SEQ ID NO:7 with no more than five additions, deletions, or substitutions.

2. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:1.

3. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEQ ID NO:7.

4. The polypeptide of claim 1 , wherein said polypeptide lacks a C-terminal tail attached to a ring structure.

5. The polypeptide of claim 1 , wherein said polypeptide comprises the sequence set forth in SEC) ID NO:34 with no more than five additions, deletions, or substitutions.

Assignees

• Mayo Foundation

Inventors

• Lee Candace Y W
• Burnett Jr John C

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• C07K14/58 Primary

  Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title